S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The Fed Can't Save Us This Time (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The Fed Can't Save Us This Time (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The Fed Can't Save Us This Time (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The Fed Can't Save Us This Time (Ad)pixel
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:ASMB

Assembly Biosciences - ASMB Stock Forecast, Price & News

$2.17
+0.01 (+0.46%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.10
$2.23
50-Day Range
$1.89
$2.34
52-Week Range
$1.32
$3.94
Volume
289,905 shs
Average Volume
494,138 shs
Market Capitalization
$104.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.90

Assembly Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
264.1% Upside
$7.90 Price Target
Short Interest
Healthy
2.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
0.21mentions of Assembly Biosciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$38,708 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.95) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

446th out of 1,108 stocks

Pharmaceutical Preparations Industry

210th out of 542 stocks

ASMB stock logo

About Assembly Biosciences (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

ASMB has been the topic of several recent analyst reports. HC Wainwright cut their price objective on shares of Assembly Biosciences from $3.50 to $2.50 in a report on Thursday, July 21st. StockNews.com raised shares of Assembly Biosciences from a "sell" rating to a "hold" rating in a research note on Tuesday, May 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Assembly Biosciences has a consensus rating of "Hold" and an average target price of $7.90.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $2.17 on Thursday. Assembly Biosciences has a one year low of $1.32 and a one year high of $3.94. The stock has a 50-day moving average price of $2.11 and a 200 day moving average price of $1.89. The company has a market capitalization of $104.63 million, a P/E ratio of -0.77 and a beta of 0.70.

Assembly Biosciences (NASDAQ:ASMB - Get Rating) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). As a group, equities research analysts forecast that Assembly Biosciences will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In related news, CEO John G. Mchutchison sold 12,314 shares of Assembly Biosciences stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $2.13, for a total value of $26,228.82. Following the completion of the transaction, the chief executive officer now directly owns 192,515 shares in the company, valued at $410,056.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 18,498 shares of company stock worth $38,708 in the last ninety days. 4.20% of the stock is owned by insiders.

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ASMB Stock News Headlines

Best Momentum Stocks to Buy for August 4th
New Strong Buy Stocks for August 4th
See More Headlines
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ASMB Company Calendar

Last Earnings
8/09/2022
Today
8/11/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ASMB
CUSIP
92282210
Employees
102
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$7.90
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+264.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-129,850,000.00
Pretax Margin
-2,051.12%

Debt

Sales & Book Value

Annual Sales
$6.25 million
Book Value
$3.53 per share

Miscellaneous

Free Float
46,191,000
Market Cap
$104.63 million
Optionable
Optionable
Beta
0.70

Social Links


Key Executives

  • Dr. John G. McHutchison A.O. (Age 64)
    FRACP, M.D., CEO, Pres & Director
    Comp: $1.47M
  • Mr. Jason A. Okazaki (Age 46)
    Chief Operating Officer
    Comp: $841.32k
  • Dr. William E. Delaney IV (Age 50)
    Ph.D., Chief Scientific Officer
    Comp: $637.9k
  • Dr. Uri A. Lopatin M.D. (Age 50)
    Co-Founder and Clinical & Scientific Advisor
  • Dr. Adam Zlotnick
    Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Mr. Michael P. Samar (Age 49)
    CFO & Principal Accounting Officer
  • Ms. Jennifer A. Troia MHROD
    SHRM-SCP, SPHR, Chief HR Officer
  • Dr. Richard J. Colonno (Age 72)
    Sr. Advisor
  • Dr. Tharaknath Rao
    Head of Microbiome Clinical Devel. & Sr. VP
  • Dr. Luisa M. Stamm M.D. (Age 46)
    Ph.D., Chief Medical Officer













ASMB Stock - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASMB shares.
View ASMB analyst ratings
or view top-rated stocks.

What is Assembly Biosciences' stock price forecast for 2022?

4 analysts have issued 1 year price targets for Assembly Biosciences' stock. Their ASMB share price forecasts range from $2.50 to $14.00. On average, they predict the company's share price to reach $7.90 in the next year. This suggests a possible upside of 264.1% from the stock's current price.
View analysts price targets for ASMB
or view top-rated stocks among Wall Street analysts.

How have ASMB shares performed in 2022?

Assembly Biosciences' stock was trading at $2.33 at the start of the year. Since then, ASMB shares have decreased by 6.9% and is now trading at $2.17.
View the best growth stocks for 2022 here
.

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ASMB earnings forecast
.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.04.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.42%), Connor Clark & Lunn Investment Management Ltd. (0.30%) and Commonwealth Equity Services LLC (0.05%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, John G Mchutchison, Luisa M Stamm, Michael P Samar, Richard James Colonno, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends
.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $2.17.

How much money does Assembly Biosciences make?

Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $104.63 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-129,850,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Assembly Biosciences have?

The company employs 102 workers across the globe.

When was Assembly Biosciences founded?

Assembly Biosciences was founded in 2005.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101.

This page (NASDAQ:ASMB) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.